Ranilair 300 Tablet contains Ranitidine 300mg, an H2 receptor antagonist that reduces stomach acid production. It is indicated for the treatment of acid reflux, gastroesophageal reflux disease (GERD), peptic ulcers, Zollinger-Ellison syndrome, and other hyperacidity-related disorders.
The tablet works by blocking H2 receptors in the stomach lining, promoting ulcer healing, reducing heartburn, and preventing acid-related tissue damage.
Ranilair 300 Tablet belongs to the gastroenterology and acid-reducing therapy segment, prescribed by gastroenterologists, surgeons, and general physicians.
For PCD pharma franchise partners, wholesalers, and exporters, Ranilair 300 Tablet offers a high-demand opportunity due to its chronic usage and widespread gastrointestinal applications. It is available for bulk supply, monopoly-based PCD franchise, third-party manufacturing, institutional distribution, and export.